Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 6701526254

Activities

Collapse all

Employment (1)

University of Glasgow: Glasgow, Scotland, GB

2019-08-01 to present | Professor of Clinical Trial Biostatistics (Robertson Centre for Biostatistics)
Employment
Source: Self-asserted source
Alex McConnachie

Funding (28)

Co-DiRECT Nepal: a community-based diet programme for remission of type 2 diabetes and amelioration of non-communicable disease risks

2024-09-30 to 2027-09-29 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.14052015
GRANT_NUMBER: MR/Z000513/1
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

CLArithromycin for post-Stroke Pneumonia (CLASP): A prospective, randomised open-label blinded-endpoint (PROBE) phase 3 multicentre trial

2024-09-01 to 2029-08-31 | Grant
National Institute for Health and Care Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.14040735
GRANT_NUMBER: NIHR158678
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

Effects of GSK1070806 (anti-IL18 mAb) on biomarkers in synovial tissue and blood of patients with rheumatoid arthritis.

2023-11-24 to 2025-05-22 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.13874775
GRANT_NUMBER: MR/Y020464/1
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

NanO2 in Large VessEL Occlusion Stroke (NOVEL): a multicentre single-blind, randomised, placebo-controlled blinded biomarker end-point clinical trial of perfluorocarbon in acute ischaemic stroke due to large vessel occlusion

2023-08-01 to 2026-07-31 | Grant
National Institute for Health and Care Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.13577780
GRANT_NUMBER: NIHR151755
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

MICA: Pulmonary Hypertension: intensification and personalisation of combination Rx (PHoenix)

2023-03-01 to 2026-02-28 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.13519672
GRANT_NUMBER: MR/W026279/1
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

Randomised control trial: cryoballoon/radiofrequency ablation of atrial fibrillation versus medical treatment for heart failure: CRAAFT-HF

2023 to 2029 | Grant
British Heart Foundation (London, GB)
Source: Self-asserted source
Alex McConnachie

Effects of GSK1070806 (anti-IL18 mAb) on biomarkers in synovial tissue and blood of patients with rheumatoid arthritis

2023 to 2025 | Grant
Medical Research Council (London, GB)
Source: Self-asserted source
Alex McConnachie

Improving uptake of breast, bowel and cervical cancer screening among Muslim women: a non-randomised feasibility study of a peer-led, faith-based intervention.

2023 to 2025 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Alex McConnachie

Delivering a Climate Resilient City through City-University Partnership: Glasgow as a Living Lab Accelerating Novel Transformation (GALLANT)

2022-01-31 to 2027-01-30 | Grant
Natural Environment Research Council (Swindon, GB)
URL: https://app.dimensions.ai/details/grant/grant.10004413
GRANT_NUMBER: NE/W005042/1
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

Use of a novel SUBCUTaneous preparation of furosemide to facilitate early supported discharge of patients with Heart Failure: a multicentre, phase II, randomised, parallel group, active comparator controlled trial.

2022 to 2025 | Grant
SQ Innovation Inc (Burlington, MA, US)
Source: Self-asserted source
Alex McConnachie

Development of in-vivo 19F Clinical MR imaging Using a Novel 19F/1H Coil in Combination with an Intravenous Perfluorocarbon (ABL-101)

2021-08-01 to 2023-10-31 | Grant
Wellcome Trust (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.10030445
GRANT_NUMBER:

222695/Z/21/Z
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

Developing an E-Mental Health Detection Tool for EarlyStage Psychosis in the Community

2021-02-01 to 2023-01-31 | Grant
Wellcome Trust (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.10029220
GRANT_NUMBER:

215793/Z/19/Z
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Study

2021 to 2026 | Grant
National Institute for Health Research (London, GB)
URL: https://fundingawards.nihr.ac.uk/award/NIHR130487
Source: Self-asserted source
Alex McConnachie

COVID-19 long term effects; a randomised clinical trial of resistance exercise and trial platform

2021 to 2024 | Grant
Chief Scientist Office (Edinburgh, GB)
Source: Self-asserted source
Alex McConnachie

The clinical impact of inherited chromosomally-integrated human herpesvirus 6 (iciHHV-6): a comprehensive analysis using UK Biobank

2020-11-01 to 2023-10-31 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9530013
GRANT_NUMBER: MR/T030941/1
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

Coronary Microvascular Angina International (i-CorMicA): a multicentre, randomised, controlled trial

2020-04 to 2025-03 | Grant
Abbott Laboratories (UK) (London, GB)
Source: Self-asserted source
Alex McConnachie

Anaesthesia Choice for Creation of ArtEriovenous FiStulae (ACCESs study). A randomised controlled trial comparing clinical (one-year functional patency rate) and costeffectiveness of regional versus local anaesthesia for primary arteriovenous fistula formation

2020 to 2024 | Grant
National Institute for Health Research (London, GB)
URL: https://fundingawards.nihr.ac.uk/award/NIHR130567
Source: Self-asserted source
Alex McConnachie

Cardiac Imaging in SARS Coronavirus disease-19 (CISCO-19)

2020 to 2024 | Grant
Chief Scientist Office (Edinburgh, GB)
Source: Self-asserted source
Alex McConnachie

EMpagliflozin to PRevent worsening of lEft ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS-MI): a multi-centre, randomized, placebo-controlled trial

2020 to 2024 | Grant
Boehringer Ingelheim (Germany) (Ingelheim am Rhein, DE)
Source: Self-asserted source
Alex McConnachie

MICA: A Developmental Trial of Personalised Medicine for Repurposing Zibotentan, a Selective Endothelin A Receptor Blocker, in Microvascular Angina.

2019-05-31 to 2023-12-31 | Grant
Medical Research Council (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.8690712
GRANT_NUMBER: MR/S018905/1
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

What is the best test for the non-invasive diagnosis of significant coronary artery disease?

2019-03 to 2024-02 | Grant
National Institute for Health Research (London, GB)
URL: https://fundingawards.nihr.ac.uk/award/CS-2018-18-ST2-007
Source: Self-asserted source
Alex McConnachie

Increasing uptake of faecal immunochemical test (FIT) bowel screening: trial of providing a suggested deadline for FIT kit return

2019 to 2024 | Grant
Cancer Research UK (London, GB)
GRANT_NUMBER:

C9227/A27877
Source: Self-asserted source
Alex McConnachie

The Impact of Type 2 Diabetes on Cardiac Metabolic Phenotype in Patients with Severe Aortic Stenosis

2019 to 2024 | Grant
Diabetes UK (London, GB)
Source: Self-asserted source
Alex McConnachie

First-in-human trial of an optimised lentiviral vector for cystic fibrosis gene therapy

2017-04-01 to 2022-12-31 | Grant
Wellcome Trust (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7158907
GRANT_NUMBER:

106878/B/15/Z
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

First-in-human trial of an optimised lentiviral vector for cystic fibrosis gene therapy

2017-04-01 to 2022-12-31 | Grant
Wellcome Trust (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7158996
GRANT_NUMBER:

106878/C/15/Z
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

First-in-human trial of an optimised lentiviral vector for cystic fibrosis gene therapy

2017-04-01 to 2022-12-31 | Grant
Wellcome Trust (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7158913
GRANT_NUMBER:

106878/Z/15/Z
Source: Self-asserted source
Alex McConnachie via DimensionsWizard

The Best Services Trial (BeST?): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health

2016-01 to 2024-02 | Grant
National Institute for Health Research (London, GB)
URL: https://fundingawards.nihr.ac.uk/award/12/211/54
Source: Self-asserted source
Alex McConnachie

GOLD imaging in acute stroke: further technology development incorporating a perfluorocarbon oxygen carrier (Oxycyte)

2015-09-17 to 2023-09-26 | Grant
Wellcome Trust (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.4579050
GRANT_NUMBER:

102567/Z/13/Z
Source: Self-asserted source
Alex McConnachie via DimensionsWizard
How many people are using ORCID?